Baxter International Inc. - BAX STOCK NEWS

Baxter International Inc. (NYSE:BAX) has announced a definitive agreement to sell its Kidney Care segment, to be named Vantive, to Carlyle for $3.8 billion. This strategic move is part of Baxter's ongoing business transformation aimed at enhancing performance and creating value for stakeholders. The transaction is expected to close in late 2024 or early 2025, subject to regulatory approvals and other conditions.

Key points:

• Baxter will receive approximately $3.5 billion in cash, with estimated net after-tax proceeds of $3 billion
• Proceeds will be used to reduce Baxter's debt
• Vantive, a leader in global kidney care, had 2023 revenues of $4.5 billion
• Post-divestiture, Baxter targets 4-5% annual operational sales growth and an adjusted operating margin of about 16.5% for 2025

Baxter International Inc. (NYSE:BAX) reported strong second-quarter 2024 results, with sales from continuing operations reaching $3.81 billion, a 3% increase on a reported basis and 4% on a constant currency basis. The company exceeded its previously issued guidance across all segments. While U.S. GAAP diluted EPS from continuing operations was ($0.62), adjusted diluted EPS was $0.68, surpassing expectations. Notably, Baxter has increased its full-year sales guidance, now projecting growth of approximately 3% on both reported and constant currency bases. The company also raised its full-year adjusted diluted EPS guidance to $2.93 to $3.01. Baxter's performance was driven by new product launches, heightened demand for various products, and operational efficiencies.

Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced that it will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024, at 7:30 a.m. Central Time. Investors and interested parties can participate in the call by pre-registering through the provided link. The call will also be webcast and accessible through Baxter's website. It's important to note that the conference call will be recorded by Baxter and is copyrighted material, which cannot be recorded or rebroadcast without Baxter's permission.

Baxter International (NYSE:BAX), a global medtech leader, has announced a quarterly cash dividend of $0.29 per share of common stock. The dividend will be payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. This declaration sets the indicated annual dividend rate at $1.16 per share of common stock. This announcement demonstrates Baxter's commitment to providing regular returns to its shareholders, which may be seen as a positive sign of the company's financial stability and confidence in its future performance.

Baxter published its 2023 Corporate Responsibility Report, emphasizing its continued commitment to global healthcare, transparency, and environmental, social, and governance (ESG) topics. The report updates Baxter's progress toward its 2030 Corporate Responsibility Commitment and Goals, highlighting key achievements such as investing over $143 million since 2021 in underserved communities, partnering with UNICEF for climate-smart projects in Egypt, and completing 150 energy conservation projects that will reduce GHG emissions by 21,100 metric tons annually from 2024. Baxter also continues to excel in workplace safety and has enhanced its reporting by adopting the TCFD framework. The company plans to conduct a double materiality assessment to align its goals with evolving corporate responsibility standards, especially in light of the proposed separation of its Kidney Care business.

Baxter, a global leader in medical technology, announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for June 12, 2024, at 8:40 a.m. Eastern Time. Baxter's CFO, Joel Grade, will represent the company, providing insights into its financial position and future directions. The presentation will be available via live webcast on Baxter's official website and can be replayed through December 9, 2024.

Baxter announced that its expanded hemodialysis (HDx) therapy, enabled by the Theranova dialyzer, has shown to reduce all-cause mortality by approximately 25% over four years compared to high-flux hemodialysis (HF HD). The findings come from a cohort study involving 1,092 dialysis patients in Colombia, presented at the ERA-EDTA Congress. Of these, 533 patients received HF HD, while 559 received HDx therapy. The study emphasized HDx therapy's efficiency in removing large-middle molecule uremic toxins, linked to inflammation and cardiovascular issues in dialysis patients. HDx therapy uses the MCO membrane for better filtration and is compatible with existing HD machines, simplifying its implementation in clinics. Over 14 million HDx treatments have been conducted worldwide.

Baxter International (NYSE:BAX), a leading medtech company, is set to present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024.

The presentation will be led by Joel Grade, Baxter's CFO, at 9:30 a.m. Eastern Time.

The event will be webcast live and accessible via Baxter's website, with a replay available until December 2, 2024.

Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, Vantive. The mission, "Extending Lives, Expanding Possibilities," will guide Vantive in developing solutions for acute and chronic kidney diseases. The new logo, featuring a "V" motif in plum color, symbolizes the company's commitment to innovative therapies, digital solutions, and advanced services.

Vantive will build upon Baxter's nearly 70-year legacy in kidney care, aiming to improve outcomes for over one million patients annually across more than 70 countries. The separation of Vantive from Baxter's Renal Care and Acute Therapies businesses is expected to occur in the second half of 2024, either through a private equity sale or a public spinoff.